Proactive Investors - Run By Investors For Investors

OptiBiotix Health inks distribution deal covering Greece and Cyprus

The unnamed local partner for CholBiome was chosen for its distribution network
cholesterol test
The company has developed CholBiome to combat cholesterol and high blood pressure

OptiBiotix Health plc (LON:OPTI) shares rose on Thursday following news the firm has signed a distribution agreement for its cholesterol and blood pressure reducing LPLDL bacteria strain in Greece and Cyprus.

The unnamed local partner for CholBiome was chosen for its customer network, which also covers the Middle East and its track record of promoting and developing products. It also has access to a number of international clinics.

READ: OptiBiotix inks agreement to manufacture LPLDL in US market

Optibiotix has granted an exclusive three-year deal, which is subject to hitting certain sales targets, in return for local product registrations. No financial details were mentioned.

In September, the company inked a distribution contract for Bulgaria, while CholBiome is now on sale in the UK online.

“This agreement is a strategic step to build the distribution sales channel for CholBiome products in the European market and eliminates intermediates in the supply chain with a shorter route to market and higher value to OptiBiotix,” said OptiBiotix commercial director Per Rehné.

“The company has already placed an initial order to be used for pre-marketing activities and we expect further orders to support a consumer launch in the first-quarter of 2019."

In early morning trading, OptiBiotix shares were up 0.8% at 66.50p.

 -- Adds share price --

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use